| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Endocrinology, Vol 6, 15-25, Copyright © 1992 by Endocrine Society
ARTICLES |
MS Steiner and ER Barrack
Department of Urology, Johns Hopkins University School of Medicine, James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland 21205.
We found previously that transforming growth factor-beta 1 (TGF beta 1) mRNA levels are markedly elevated in rat prostate cancer (Dunning R3327 sublines) compared to levels in normal prostate. Our goal was to determine whether elevated expression of TGF beta 1 is biologically relevant to prostate cancer growth in vivo. We chose as our model the R3327-MATLyLu prostate cancer epithelial cell line, which produces metastatic anaplastic tumors when reinoculated in vivo. Our approach was to stably transfect MATLyLu cells with an expression vector that codes for latent TGF beta 1 and to isolate subclones of cells that over- expressed TGF beta 1 mRNA. We also isolated a subclone of MATLyLu cells transfected with a control vector lacking the TGF beta 1 cDNA insert. We then studied the growth of these cells in vivo and in vitro. Twenty days after sc inoculation of 10(6) cells in vivo, TGF beta 1- overproducing MATLyLu tumors were 50% larger, markedly less necrotic, and produced more extensive metastatic disease (lung metastases in 73% of all lobes and lymph node metastases in 88% of animals) compared to control MATLyLu tumors (lung metastases, 21%; lymph node metastases, 7%). Thus, TGF beta 1 produced in vivo is biologically active and can promote prostate cancer growth, viability, and aggressiveness, perhaps via effects on the host and/or on the tumor cells themselves. When followed in vitro, TGF beta 1-overproducing cells became growth inhibited, but this effect was transient as cells subsequently resumed proliferating. Growth inhibition was due to TGF beta, because it could be prevented by TGF beta-neutralizing antibody. Therefore, prostate cancer cells can activate and respond to secreted latent TGF beta 1, and although the cells are transiently inhibited in vitro, there is no net inhibition of growth. The ability of the cells to respond to endogenously produced TGF beta 1 suggests that TGF beta 1 overexpression enhances tumor growth in vivo at least in part via an effect of TGF beta 1 on the tumor cells themselves.
This article has been cited by other articles:
 |
|
 |
|
  J. Kanter, S. Y. Khan, M. Kelher, L. Gore, and C. C. Silliman Oncogenic and Angiogenic Growth Factors Accumulate during Routine Storage of Apheresis Platelet Concentrates Clin. Cancer Res., June 15, 2008; 14(12): 3942 - 3947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bellezza, H. Neuwirt, C. Nemes, I. T. Cavarretta, M. Puhr, H. Steiner, A. Minelli, G. Bartsch, F. Offner, A. Hobisch, et al. Suppressor of Cytokine Signaling-3 Antagonizes cAMP Effects on Proliferation and Apoptosis and Is Expressed in Human Prostate Cancer Am. J. Pathol., December 1, 2006; 169(6): 2199 - 2208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zhang, J. Lee, S. Lu, C. A. Pettaway, and Z. Dong Blockade of Transforming Growth Factor-{beta} Signaling Suppresses Progression of Androgen-Independent Human Prostate Cancer in Nude Mice Clin. Cancer Res., June 15, 2005; 11(12): 4512 - 4520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.S. Prime, M. Davies, M. Pring, and I.C. Paterson THE ROLE OF TGF-{beta} IN EPITHELIAL MALIGNANCY AND ITS RELEVANCE TO THE PATHOGENESIS OF ORAL CANCER (PART II) Crit. Rev. Oral. Biol. Med., November 1, 2004; 15(6): 337 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Blaszczyk, B. A. Masri, N. R. Mawji, T. Ueda, G. McAlinden, C. P. Duncan, N. Bruchovsky, H.-U. Schweikert, D. Schnabel, E. C. Jones, et al. Osteoblast-Derived Factors Induce Androgen-Independent Proliferation and Expression of Prostate-Specific Antigen in Human Prostate Cancer Cells Clin. Cancer Res., March 1, 2004; 10(5): 1860 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Morris and H. I. Scher Clinical Approaches to Osseous Metastases in Prostate Cancer Oncologist, April 1, 2003; 8(2): 161 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Tuxhorn, G. E. Ayala, M. J. Smith, V. C. Smith, T. D. Dang, and D. R. Rowley Reactive Stroma in Human Prostate Cancer: Induction of Myofibroblast Phenotype and Extracellular Matrix Remodeling Clin. Cancer Res., September 1, 2002; 8(9): 2912 - 2923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zhang, W. Lu, and Z. Dong Tumor-infiltrating Macrophages Are Involved in Suppressing Growth and Metastasis of Human Prostate Cancer Cells by INF-{beta} Gene Therapy in Nude Mice Clin. Cancer Res., September 1, 2002; 8(9): 2942 - 2951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Shariat, M. Shalev, A. Menesses-Diaz, I. Y. Kim, M. W. Kattan, T. M. Wheeler, and K. M. Slawin Preoperative Plasma Levels of Transforming Growth Factor Beta1 (TGF-{beta}1) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy J. Clin. Oncol., June 1, 2001; 19(11): 2856 - 2864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Tang, K. de Castro, H. E. Barnes, W. T. Parks, L. Stewart, E. P. Bottinger, D. Danielpour, and L. M. Wakefield Loss of Responsiveness to Transforming Growth Factor {beta} Induces Malignant Transformation of Nontumorigenic Rat Prostate Epithelial Cells Cancer Res., October 1, 1999; 59(19): 4834 - 4842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bandyopadhyay, Y. Zhu, M. L. Cibull, L. Bao, C. Chen, and L. Sun A Soluble Transforming Growth Factor {beta} Type III Receptor Suppresses Tumorigenicity and Metastasis of Human Breast Cancer MDA-MB-231 Cells Cancer Res., October 1, 1999; 59(19): 5041 - 5046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-C. Ye, J. M. Foster, W. Li, J. Liang, E. Zborowska, S. Venkateswarlu, J. Gong, M. G. Brattain, and J. K. V. Willson Contextual Effects of Transforming Growth Factor {beta} on the Tumorigenicity of Human Colon Carcinoma Cells Cancer Res., September 1, 1999; 59(18): 4725 - 4731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. FRIESS, X.-Z. GUO, B.-C. NAN, O. KLEEFF, and M. W. BUCHLER Growth Factors and Cytokines in Pancreatic Carcinogenesis Ann. N.Y. Acad. Sci., June 30, 1999; 880(1): 110 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Brodin, P. t. Dijke, K. Funa, C.-H. Heldin, and M. Landstrom Increased Smad Expression and Activation Are Associated with Apoptosis in Normal and Malignant Prostate after Castration Cancer Res., June 1, 1999; 59(11): 2731 - 2738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Won, H. Kim, E. J. Park, Y. Hong, S.-J. Kim, and Y. Yun Tumorigenicity of Mouse Thymoma Is Suppressed by Soluble Type II Transforming Growth Factor {beta} Receptor Therapy Cancer Res., March 1, 1999; 59(6): 1273 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Russell, S. Bennett, and P. Stricker Growth factor involvement in progression of prostate cancer Clin. Chem., April 1, 1998; 44(4): 705 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Gerdes, M. Larsen, L. McBride, T. D. Dang, B. Lu, and D. R. Rowley Localization of Transforming Growth Factor-b1 and Type II Receptor in Developing Normal Human Prostate and Carcinoma Tissues J. Histochem. Cytochem., March 1, 1998; 46(3): 379 - 388. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]
|
|
|
|
 |
|
 N.-S. Chang Hyaluronidase enhancement of TNF-mediated cell death is reversed by TGF-beta 1 Am J Physiol Cell Physiol, December 1, 1997; 273(6): C1987 - C1994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sun and C. Chen Expression of Transforming Growth Factor beta Type III Receptor Suppresses Tumorigenicity of Human Breast Cancer MDA-MB-231 Cells J. Biol. Chem., October 3, 1997; 272(40): 25367 - 25372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. COLASANTE, N. MASCETRA, M. BRUNETTI, G. LATTANZIO, M. DIODORO, S. CALTAGIRONE, P. MUSIANI, and F. B. AIELLO Transforming Growth Factor beta 1, Interleukin-8 and Interleukin-1, in Non-Small-Cell Lung Tumors Am. J. Respir. Crit. Care Med., September 1, 1997; 156(3): 968 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Woo, H. H. Cha, K. L. Singer, and G. L. Firestone Antagonistic Regulation of Tight Junction Dynamics by Glucocorticoids and Transforming Growth Factor-beta in Mouse Mammary Epithelial Cells J. Biol. Chem., January 5, 1996; 271(1): 404 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Miyoshi, A. Nishikawa, Y. Ihara, H. Saito, N. Uozumi, N. Hayashi, H. Fusamoto, T. Kamada, and N. Taniguchi Transforming Growth Factor beta Up-regulates Expression of the N-Acetylglucosaminyltransferase V Gene in Mouse Melanoma Cells J. Biol. Chem., March 17, 1995; 270(11): 6216 - 6220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A B Glick, M M Lee, N Darwiche, A B Kulkarni, S Karlsson, and S H Yuspa Targeted deletion of the TGF-beta 1 gene causes rapid progression to squamous cell carcinoma. Genes & Dev., October 15, 1994; 8(20): 2429 - 2440. [Abstract] [PDF]
|
|
|
|
|
|
A. Choudhury, R. K. Singh, N. Moniaux, T. H. El-Metwally, J.-P. Aubert, and S. K. Batra Retinoic Acid-dependent Transforming Growth Factor-beta 2-mediated Induction of MUC4 Mucin Expression in Human Pancreatic Tumor Cells Follows Retinoic Acid Receptor-alpha Signaling Pathway J. Biol. Chem., October 20, 2000; 275(43): 33929 - 33936. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
